Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-year Prospective Study of Health-related Quality of Life in Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad
2017-002632-17Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in multiple sclerosis (MS), sponsored by Merck KGaA. Primary endpoints: Change in MSQoL-54 physical health composite score at 24 months and Change in MSQoL-54 mental health composite score at 24 months. Started Dec 2017; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-002632-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002632-17.